Multiple Sclerosis
📧 Sign up to get email alerts when something new happens for Multiple Sclerosis.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2022-09-07FDA Approved: FINGOLIMOD — Original Application (Solco Healthcare US, LLC)
The FDA approved the original application for fingolimod from Solco Healthcare US, LLC, enabling a generic fingolimod product for multiple s…
-
FDA approval · 2022-09-02FDA Approved: BETASERON — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)
FDA approved a supplemental application for BETASERON (interferon beta-1b) from Bayer HealthCare Pharmaceuticals Inc., resulting in an updat…
-
FDA approval · 2022-09-02FDA Approved: KESIMPTA — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA has approved a supplemental application for Kesimpta (ofatumumab) from Novartis Pharmaceuticals Corporation.
-
CLINICAL_TRIALS trial_result · 2022-08-25Clinical Trial Update: tDCS to Lower Neuropathic Pain and Fatigue in People With Multiple Sclerosis [NA]
A completed clinical trial evaluating transcranial direct current stimulation (tDCS) to reduce neuropathic pain and fatigue in people with m…
-
FDA approval · 2022-08-19FDA Approved: GLATIRAMER ACETATE — Supplemental Application (Mylan Pharmaceuticals Inc.)
The FDA approved a supplemental application for glatiramer acetate from Mylan Pharmaceuticals, enabling the marketing of a generic version o…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2022-08-19FDA Approved: GLATIRAMER ACETATE — Supplemental Application (Mylan Pharmaceuticals Inc.)
The FDA approved a supplemental application for glatiramer acetate from Mylan Pharmaceuticals Inc., indicating approval of a generic version…
-
CLINICAL_TRIALS trial_result · 2022-08-09Clinical Trial Update: Botulinum Toxin in Patients With Spastic Lower Limb Paresis Associated With Multiple Sclerosis [Phase 3]
A Phase 3 clinical trial evaluating botulinum toxin for spastic lower limb paresis in patients with multiple sclerosis has completed.
-
FDA label_change · 2022-08-03FDA Approved: OCREVUS — Supplemental Application (Genentech, Inc.)
FDA approved a supplemental application for OCREVUS (ocrelizumab) filed by Genentech, indicating an update to the product labeling for this …
-
FDA approval · 2022-07-28FDA Approved: DALFAMPRIDINE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
The FDA approved a supplemental application for dalfampridine from Sun Pharmaceutical Industries, Inc. (ANDA208292), supporting the generic …
-
FDA approval · 2022-07-15FDA Approved: TERIFLUNOMIDE — Supplemental Application (Teva Pharmaceuticals, Inc.)
The FDA approved a supplemental application for Teriflunomide from Teva Pharmaceuticals, Inc. This action indicates FDA approval of a supple…
-
CLINICAL_TRIALS trial_result · 2022-07-15Clinical Trial Update: A Study to Investigate the Safety and Effectiveness of Arbaclofen Extended-Release Tablets for Patients With MS [Phase 3]
Phase 3 trial investigating the safety and effectiveness of arbaclofen extended-release tablets in patients with multiple sclerosis-related …
-
CLINICAL_TRIALS trial_result · 2022-07-15Clinical Trial Update: A Study to Evaluate the Long-term Safety of Arbaclofen Extended-Release Tablets for Patients With Spasticity Due to MS [Phase 3]
Phase 3 trial assessing long-term safety of arbaclofen extended-release tablets for spasticity due to multiple sclerosis; study completed wi…
-
FDA approval · 2022-07-15FDA Approved: TERIFLUNOMIDE — Supplemental Application (Accord Healthcare Inc.)
FDA approved a supplemental application for Accord Healthcare Inc.'s Teriflunomide, finalizing regulatory action on the generic product.
-
CLINICAL_TRIALS trial_result · 2022-07-12Clinical Trial Update: A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT [Phase 3]
A Phase 3 study evaluating alemtuzumab in pediatric relapsing-remitting multiple sclerosis with disease activity on prior disease-modifying …
-
CLINICAL_TRIALS trial_result · 2022-06-24Clinical Trial Update: A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1 [Phase 3]
Phase 3 trial update for ALKS 8700 in adults with relapsing-remitting multiple sclerosis (EVOLVE-MS-1) has completed with results posted.
-
FDA approval · 2022-06-10FDA Approved: MAYZENT — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for Mayzent (siponimod) from Novartis Pharmaceuticals Corporation.
-
FDA approval · 2022-06-10FDA Approved: TIZANIDINE HYDROCHLORIDE — Supplemental Application (Alembic Pharmaceuticals Limited)
The FDA approved a supplemental application for a generic tizanidine hydrochloride product submitted by Alembic Pharmaceuticals Limited unde…
-
FDA approval · 2022-06-10FDA Approved: TIZANIDINE HYDROCHLORIDE — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for Tizanidine Hydrochloride from Aurobindo Pharma Limited under an ANDA. This action confirms regul…
-
CLINICAL_TRIALS trial_result · 2022-06-02Clinical Trial Update: Outcomes Mandate National Integration With Cannabis as Medicine [Phase 2]
Phase 2 clinical trial update focusing on integrating cannabis as medicine for various chronic pain conditions, with status currently UNKNOW…
-
FDA approval · 2022-05-25FDA Approved: TIZANIDINE HYDROCHLORIDE — Supplemental Application (Zydus Lifesciences Limited)
FDA approves a supplemental application for tizanidine hydrochloride submitted by Zydus Lifesciences Limited. This action completes FDA appr…
-
FDA approval · 2022-05-25FDA Approved: TIZANIDINE HYDROCHLORIDE — Supplemental Application (Nivagen Pharmaceuticals, Inc.)
FDA approved a supplemental application for tizanidine hydrochloride by Nivagen Pharmaceuticals, Inc., representing a regulatory update for …
-
CLINICAL_TRIALS trial_result · 2022-05-11Clinical Trial Update: Assessment of Tecfidera® in Radiologically Isolated Syndrome (RIS) [Phase 4]
Phase 4 clinical trial assessing Tecfidera in radiologically isolated syndrome completed with results posted in 2022.
-
CLINICAL_TRIALS trial_result · 2022-05-05Clinical Trial Update: Long-Term Outcomes and Durability of Effect Following Treatment With Cladribine Tablets for MS (CLASSIC-MS) [Phase 4]
Phase 4 clinical trial assessing long-term outcomes and durability of effect after cladribine tablets in multiple sclerosis patients.
-
CLINICAL_TRIALS trial_result · 2022-04-28Clinical Trial Update: Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS) [Phase 2]
Phase 2 trial evaluating BIIB033 (Opicinumab) as add-on therapy to existing disease-modifying therapies in relapsing multiple sclerosis; stu…
-
CLINICAL_TRIALS withdrawal · 2022-04-27Clinical Trial Update: To Assess Effects of Arbaclofen ER Tablets Compared With Placebo on Sperm Parameters in Male Subjects With MS [Phase 3]
Phase 3 trial assessing arbaclofen ER tablets vs placebo on sperm parameters in male MS patients was withdrawn.